Variability of Oxaliplatin-Induced Neuropathic Pain Symptoms in Each Cycle and Its Implications on the Management of Colorectal Cancer Patients: A Retrospective Study in South Western Sydney Local Health District Hospitals, Sydney, Australia

Table 2

Baseline characteristics of study subjects.

Variable	Frequency (n)	Percentage (%)
Type of colorectal cancer
Adenocarcinoma of caecum	61	18.9
Adenocarcinoma of ascending colon	30	9.3
Adenocarcinoma of transverse colon	21	6.5
Adenocarcinoma of descending colon	10	3.1
Adenocarcinoma of sigmoid colon	109	33.9
Adenocarcinoma of rectosigmoid junction	28	8.7
Adenocarcinoma of rectum	63	19.6
Starting dose of oxaliplatin (IV) in the treatment regimen
85 mg/m^2	214	66.5
100 mg/m^2	5	1.6
130 mg/m^2	103	32
Starting dose of fluorouracil in the treatment regimen
400 mg/m^2 (IV) plus 2400 mg/m^2 (CIVP)	211	65.5
NA	111	34.5
Starting dose of folinic acid (FA) in the treatment regimen
50 mg/m^2	1	0.3
200 mg/m^2	207	64.3
400 mg/m^2	3	0.9
NA	111	34.5
Treatment regimen	Adjuvant: n (%)	Metastatic: n (%)
FOLFOX	144 (44.7)	67 (20.8)
XELOX	84 (26.1)	21 (6.5)
FOLFOX + avastin	1 (0.3)	0 (0)
Oxaliplatin alone	4 (1.2)	1 (0.3)

NA: not applicable; CIVP: central intravenous pump; IV=intravenous.